Micro Pharmaceuticals

Albert David Ltd.

ALBERTDAVD

₹808.6

1.01% (8.05)

Market Cap

₹460 Cr.

P/E

26.73

Albert David Ltd.

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Albert David Ltd. Shareprice

Has the share price of Albert David grown faster than its competition?

Albert David has given better returns compared to its competitors.
Albert David has grown at ~14.53% over the last 3yrs while peers have grown at a median rate of 10.85%

Is Albert David stock expensive?

Yes, Albert David is expensive.
Latest PE of Albert David is 26.73, while 3 year average PE is 11.47.
Also latest EV/EBITDA of Albert David is 154 while 3yr average is 15.2.

View FAQ's On Business

Growth Table

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	-25.21	15.23	14.53	14.48	9.08	11.19	11.06	11.87	11.39	11.01
TTM EPS CAGR	-76.97	-33.30	-20.66	10.79	-1.70	-0.10	3.19	0.77	6.71	6.34
Sales CAGR	-4.61	0.61	3.32	8.72	1.51	1.46	2.60	1.34	0.68	0.72
PAT Margin (Abs Growth)	9.63	9.00	11.17	13.99	11.67	16.49	14.46	5.29	15.57	15.86
PE CAGR	225	72.75	44.35	3.33	10.97	11.30	7.63	11.02	4.39	4.39
CFO CAGR	333	6.11	7.52	10.74	7.38	7.18	12.57	-4.90	5.62	8.16

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	265	351	361	376	398	405	475	512	604	511
Non Current Assets	72.22	121	122	112	130	127	147	119	123	157
Net Block	44.44	86.76	82.84	77.09	91.00	83.96	87.68	80.02	83.39	98.78
Capital Work in Progress	5.01	8.67	5.25	5.06	1.52	0.75	0.81	2.72	6.74	1.73
Intangible Assets Under Development	1.66	2.09	2.43	2.46	—	—	—	—	0.06	0.18
Long Term Investments	16.50	16.75	18.90	21.43	24.17	23.86	26.56	25.88	18.84	17.95
Current Assets	196	234	243	263	268	278	327	394	478	354
Inventory	48.54	50.66	43.21	44.06	42.72	35.75	39.18	50.68	43.61	63.90
Accounts Receivable	35.46	33.07	27.32	21.77	30.13	19.49	25.00	30.33	29.33	27.37
Short Term Investments	31.04	42.16	48.98	91.55	97.61	114	157	167	254	242
Cash & Bank Balances	23.17	14.79	25.66	7.13	6.75	35.37	18.56	25.22	31.16	1.69
Liabilities	265	351	361	376	398	405	475	512	604	511
Shareholders Funds	137	183	186	210	223	244	279	312	383	392
Share Capital	5.71	5.71	5.71	5.71	5.71	5.71	5.71	5.71	5.71	5.71
Reserves	131	177	180	205	217	239	274	306	377	387
Non Current Liabilities	7.97	9.29	14.73	19.91	26.79	25.56	14.43	11.90	15.96	14.75
Secured Loans	—	—	—	—	1.44	0.39	1.11	—	—	—
Unsecured Loans	—	—	—	—	—	—	—	—	—	—
Current Liabilities	120	159	160	145	149	135	181	189	205	104
Accounts Payable	26.55	27.34	31.75	29.69	38.22	24.67	30.38	32.14	33.95	37.56
Short Term Loans	20.23	30.03	27.64	0.44	—	0.43	3.77	3.97	2.10	10.05

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Sales	323	295	290	317	321	247	314	342	362	346
Operating Expenses	291	277	275	288	290	228	273	297	315	343
Raw Material	39.11	36.35	27.04	27.37	25.01	20.25	23.73	27.70	28.44	70.15
Chemicals	10.58	12.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Food & Aroma Chemicals	8.79	9.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Herbal Products	2.11	2.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Minerals	3.19	1.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Others	12.88	9.31	27.04	27.37	25.01	20.25	23.73	27.70	28.44	—
Stainless Steel	1.06	0.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Vitamins	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Material Cost (%)	18.57	18.92	20.55	23.67	23.16	28.15	27.81	25.57	25.08	16.14
Employee Cost	81.60	83.18	86.30	89.89	90.34	82.70	85.38	81.07	88.43	109
Power & Fuel Cost	16.30	12.04	12.57	12.77	13.83	8.52	13.22	18.85	16.42	—
Operating Profit	31.30	18.12	15.81	29.25	30.50	19.28	40.93	44.47	46.99	3.03
Other Income	1.97	15.84	9.50	21.49	7.11	17.18	15.84	15.40	57.55	29.58
OPM (%)	9.70	6.13	5.44	9.22	9.51	7.79	13.06	13.02	12.96	0.88
Depreciation and Amortisation	9.00	7.52	8.37	7.02	7.67	8.23	8.81	8.55	6.83	6.97
Interest	2.05	0.90	1.01	0.86	0.98	0.78	0.67	0.58	0.43	0.41
Profit Before Tax	63.02	25.54	15.93	42.86	28.95	27.44	47.30	50.74	97.29	25.23
Tax	15.02	9.59	6.09	16.22	9.79	5.30	12.04	14.56	21.87	8.03
Net Profit	48.00	15.96	9.84	26.64	19.17	22.14	35.26	36.17	75.42	17.20
Number of shares(Crs)	0.57	0.57	0.57	0.57	0.57	0.57	0.57	0.57	0.57	—
Dividend Payout Ratio(%)	6.54	19.67	31.90	12.85	20.84	15.46	14.57	14.20	8.70	—

TTM Values as of Mar 2025

Cash Flow

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash from Operating Activity	68.04	19.87	30.01	31.87	30.25	36.61	40.41	10.52	45.50	-28.44
Profit Before Tax	22.21	25.54	15.93	42.86	28.95	27.44	47.30	50.74	97.29	25.23
Adjustments	63.00	2.23	2.80	-12.88	7.23	-7.45	-5.53	1.32	-44.44	-15.78
OCF Before Working Capital	85.21	27.77	18.73	29.98	36.18	19.99	41.77	52.06	52.84	9.44
Working Capital Changes	9.75	3.16	18.52	8.22	9.27	18.92	11.22	-25.84	8.77	-29.37
Taxes Paid	-26.93	-11.07	-7.23	-6.34	-15.20	-2.30	-12.58	-15.71	-16.11	-8.51
Cash from Investing Activity	-38.34	-36.60	-11.03	-19.07	-20.00	-38.68	-39.70	-5.00	-33.25	23.30
Net Fixed Assets Purchased	-5.59	-20.00	1.16	13.52	-15.06	-1.31	-8.63	-4.83	-10.87	-14.57
Fixed Assets Purchased	-5.74	-20.07	-3.77	-1.96	-15.42	-1.63	-11.08	-5.24	-10.87	-14.86
Fixed Assets Sold	0.15	0.07	4.93	15.48	0.37	0.33	2.45	0.41	0.00	0.28
Investment Purchased	-70.87	-121	-136	-155	-152	-40.11	-41.73	-6.28	-40.90	—
Investment Sold	38.58	112	129	116	142	97.44	—	7.60	7.66	1.59
Interest Recieved	0.18	0.81	1.22	2.07	0.92	2.73	2.58	2.16	5.44	3.38
Dividends Recieved	0.20	0.15	0.28	1.68	2.64	—	0.08	0.36	0.42	0.24
Subsidiary Investments	—	—	—	—	—	—	—	—	—	—
Cash from Financing Activity	-17.93	6.69	-4.56	-17.09	-10.33	-1.71	-1.59	-6.36	-8.27	0.11
Proceeds From Shares	—	—	—	—	—	—	—	—	—	—
Net Long Term Borrowings	-8.00	0.00	0.00	0.00	-0.92	-1.22	-1.16	0.00	0.00	0.00
Proceeds From Borrowings	—	—	—	—	—	—	—	—	—	—
Repayment From Borrowings	-8.00	—	—	—	-0.92	-1.22	-1.16	—	—	—
Interest Paid	-1.74	-0.53	-0.46	-0.42	-0.53	-0.45	-0.33	-0.28	-0.24	-0.25
Dividend Paid	-6.31	-1.23	-3.77	-3.75	-8.88	-0.04	-3.44	-5.15	-5.17	-6.55
Net Cash Flow	11.77	-10.04	14.42	-4.29	-0.08	-3.78	-0.88	-0.84	3.98	-5.03
Opening Cash & Cash Equivalents	9.77	5.87	-3.92	10.71	6.41	6.42	3.08	2.28	1.45	5.44
Effect of FX	0.18	0.26	0.20	-0.01	0.08	0.00	0.08	0.01	0.01	0.00
Closing Cash & Cash Equivalents	21.72	-3.92	10.71	6.41	6.42	2.64	2.28	1.45	5.44	0.42
Net Capex (est)	5.59	20.00	-1.16	-13.52	15.06	1.31	8.63	4.83	10.87	14.57
Free Cash Flow (est)	62.45	-0.13	31.17	45.39	15.20	35.30	31.78	5.69	34.63	-43.01

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	0.85	1.23	1.16	1.25	1.50	1.52	1.79	1.59	1.82	2.11
Liquid Assets (Crs)	106	147	184	200	219	226	242	288	343	434
Current Liabilities (Crs)	125	120	159	160	145	149	135	181	189	205
Current Ratio	1.27	1.64	1.48	1.52	1.81	1.81	2.05	1.81	2.09	2.33
Current Assets (Crs)	158	196	234	243	263	268	278	327	394	478
Current Liabilities (Crs)	125	120	159	160	145	149	135	181	189	205
Interest Coverage Ratio	7.77	31.69	29.37	16.73	50.78	30.41	36.00	71.35	87.91	226
EBIT (Crs)	23.26	24.26	26.45	16.94	43.72	29.94	28.23	47.97	51.32	97.72
Interest Expenses (Crs)	2.99	2.05	0.90	1.01	0.86	0.98	0.78	0.67	0.58	0.43
Fixed Asset Turnover	1.92	1.88	1.33	1.51	1.65	1.52	1.17	1.41	1.54	1.57
Net Sales (Crs)	322	323	295	290	317	321	247	314	342	362
Fixed Assets (Crs)	168	172	221	192	192	212	212	223	222	231
Cash Conversion Cycle	60.29	61.60	61.84	46.91	32.19	28.18	-75.01	-49.30	-57.15	-59.38
Inventory Days	52.00	55.04	59.07	55.23	47.78	46.93	54.98	41.36	45.48	44.87
Days Receivable	45.67	41.85	40.81	35.54	26.88	28.06	34.76	24.56	28.00	28.39
Days Payable	37.38	35.29	38.04	43.86	42.46	46.81	165	115	131	133
Debt to Equity Ratio	0.32	0.15	0.16	0.15	0.00	0.01	0.01	0.02	0.02	0.01
Total Debt (Crs)	30.10	20.23	30.03	27.64	0.44	2.05	1.62	4.55	4.70	2.72
Shareholders Equity (Crs)	92.82	137	183	186	210	223	244	279	312	383
Free Cash Flow/Sales (%)	5.72	19.36	-0.05	10.74	14.31	4.74	14.27	10.14	1.66	9.55
Free Cash Flow(est) (Crs)	18.40	62.45	-0.13	31.17	45.39	15.20	35.30	31.78	5.69	34.63
Net Sales (Crs)	322	323	295	290	317	321	247	314	342	362
Profitability Ratios
Gross Margin (%)	80.03	81.43	81.08	79.45	76.33	76.84	71.85	72.19	74.43	74.92
Op Profit Margin (%)	11.46	9.70	6.13	5.44	9.22	9.51	7.79	13.06	13.02	12.96
Operating Profit (Crs)	38.68	33.26	33.96	25.31	50.74	37.61	36.46	56.78	59.87	105
Net Sales (Crs)	322	323	295	290	317	321	247	314	342	362
Net Profit Margin (%)	4.26	14.88	5.40	3.39	8.40	5.98	8.95	11.25	10.59	20.81
Net Profit (Crs)	13.70	48.00	15.96	9.84	26.64	19.17	22.14	35.26	36.17	75.42
Net Sales (Crs)	322	323	295	290	317	321	247	314	342	362
ROCE (%)	21.78	16.76	13.75	8.44	18.98	12.00	10.46	16.32	15.87	24.49
EBIT (Crs)	23.26	24.26	26.45	16.94	43.72	29.94	28.23	47.97	51.32	97.72
Capital Employed (Crs)	107	145	192	201	230	250	270	294	323	399
Return on Assets (%)	5.92	18.14	4.55	2.73	7.09	4.81	5.46	7.42	7.06	12.48
Net Profit (Crs)	13.70	48.00	15.96	9.84	26.64	19.17	22.14	35.26	36.17	75.42
Total Assets (Crs)	231	265	351	361	376	398	405	475	512	604
ROIC (%)	18.65	16.56	4.19	3.13	7.18	7.34	4.51	9.68	9.54	8.96
Op Profit after Taxes (Crs)	14.51	16.98	6.62	4.60	13.82	15.11	8.91	23.95	25.61	31.14
Invested Capital (Crs)	77.79	103	158	147	192	206	198	247	269	348
ROE (%)	14.76	35.08	8.72	5.29	12.66	8.60	9.06	12.62	11.61	19.69
Net Profit Margin (%)	4.26	14.88	5.40	3.39	8.40	5.98	8.95	11.25	10.59	20.81
Asset Turnover ratio	1.39	1.22	0.84	0.80	0.84	0.81	0.61	0.66	0.67	0.60
Equity Multiplier	2.49	1.93	1.92	1.94	1.79	1.79	1.66	1.70	1.64	1.58
Adjusted EPS	24.01	84.10	27.96	17.24	46.68	33.59	38.80	61.78	63.38	132
Valuation Ratios
P/E	11.45	3.55	11.40	21.14	8.44	9.58	9.71	8.61	8.08	8.14
Price to Book	1.69	1.25	0.99	1.12	1.07	0.82	0.88	1.09	0.94	1.60
EV/EBITDA	4.58	5.04	5.80	8.30	4.30	4.76	4.97	5.10	4.54	5.60
Dividend Yield (%)	2.00	1.84	1.73	1.51	1.52	2.18	1.59	1.69	1.76	1.07

Quarterly Results

Albert David Ltd.
Medico Remedies
Loading...
Lyka Labs
Loading...

In Rs. Cr.	Dec'22	Mar'23	Jun'23	Sep'23	Dec'23	Mar'24	Jun'24	Sep'24	Dec'24	Mar'25
Net Sales	74.57	81.42	91.95	93.18	88.28	89.06	89.36	98.44	83.08	74.89
Operating Expenses	66.28	71.83	78.96	77.21	79.93	79.49	88.48	92.21	82.41	79.64
Increase/Decrease in Stock	-3.57	-3.73	0.91	3.00	1.55	-7.23	1.88	1.32	-7.41	-10.12
Raw Material	16.68	12.86	15.57	14.94	16.03	17.35	15.50	16.34	17.43	20.89
Employee Cost	20.30	17.23	22.20	20.43	23.09	22.72	28.37	29.31	28.61	22.68
Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gen_AdminExpenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Miscellaneous Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Profit	8.29	9.59	12.99	15.97	8.35	9.57	0.88	6.22	0.67	-4.75
Other Income	7.46	0.01	18.13	12.10	16.88	10.44	23.06	20.64	-9.01	-5.11
Interest	0.11	0.11	0.08	0.06	0.12	0.07	0.09	0.06	0.13	0.13
PBDT	15.64	9.49	31.04	28.01	25.12	19.94	23.85	26.80	-8.46	-9.99
Depreciation and Amortization	2.06	2.30	1.85	1.46	1.68	1.83	1.78	1.67	1.70	1.82
Profit Before Tax	13.58	7.19	29.19	26.55	23.44	18.11	22.06	25.13	-10.16	-11.81
Tax	3.03	3.46	5.70	6.25	4.72	5.20	3.22	7.06	-0.77	-1.48
Profit After Tax	10.55	3.73	23.49	20.30	18.72	12.91	18.84	18.07	-9.39	-10.33
Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit	10.55	3.73	23.49	20.30	18.72	12.91	18.84	18.07	-9.39	-10.33
Quarterly Ratios
EPS	18.48	6.54	41.16	35.57	32.80	22.62	33.02	31.66	-16.45	-18.10
Operating Profit Margin	11.11	11.78	14.13	17.14	9.46	10.74	0.98	6.32	0.81	-6.34
Net Profit Margin	14.15	4.59	25.55	21.79	21.20	14.50	21.09	18.36	-11.30	-13.79

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

35.50%

Implied Growth Rate over a 5 year period*

12.00%

Implied Growth Rate over a 10 year period*

5.00%

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Raphson method.

Learn how to use Reverse DCF

FAQs on Albert David Ltd. Financials

How strong is Albert David balance sheet?

Balance sheet of Albert David is strong.
It shouldn't have solvency or liquidity issues.

Is the debt of Albert David increasing or decreasing?

Yes, The net debt of Albert David is increasing.
Latest net debt of Albert David is ₹8.36 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹59.58 Crs.

Is the profitablity of Albert David improving?

The profit is oscillating.
The profit of Albert David is ₹17.2 Crs for TTM, ₹75.42 Crs for Mar 2024 and ₹36.17 Crs for Mar 2023.

Does Albert David pay decent dividends?

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Albert David latest dividend payout ratio is 8.7% and 3yr average dividend payout ratio is 12.49%

How has Albert David allocated its funds?

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Albert David Ltd.

Albert David Ltd.

Has the share price of Albert David grown faster than its competition?

Is Albert David stock expensive?

How strong is Albert David balance sheet?

Is the debt of Albert David increasing or decreasing?

Is the profitablity of Albert David improving?

Does Albert David pay decent dividends?

How has Albert David allocated its funds?

SIGN UP FOR FREE